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Abstract 30 
Haemophilus parasuis causes Glässer’s disease and pneumonia in pigs. Indirect haemagglutination (IHA) is 31 
used to serotype this bacterium, distinguishing fifteen serovars with some non-typeable isolates. The capsule 32 
loci of the fifteen reference strains were annotated and significant genetic variation was identified between 33 
serovars, with the exception of serovars 5 and 12. A capsule locus and in silico serovar was identified for all 34 
but two non-typeable isolates in our collection of over 200 isolates. Here we describe the development of a 35 
multiplex PCR, based on variation within the capsule loci of the fifteen serovars of H. parasuis, for rapid 36 
molecular serotyping. The mPCR distinguished between all previously described serovars except 5 and 12, 37 
which were detected by the same pair of primers. The detection limit of the mPCR was 4.29x105 ng/µl 38 
bacterial genomic DNA and high specificity was indicated by the absence of reactivity against closely 39 
related commensal Pasteurellaceae and other bacterial pathogens of pigs. A subset of 150 isolates from a 40 
previously sequenced H. parasuis collection was used to validate the mPCR with 100% accuracy compared 41 
to in silico results. In addition, the two in silico non-typeable isolates were typeable using the mPCR. A 42 
further 84 isolates were analysed by mPCR and compared to IHA serotyping results with 90% concordance 43 
(excluding those non-typeable by IHA). The mPCR was faster, more sensitive, and more specific than IHA 44 
enabling the differentiation of fourteen of the fifteen serovars of H. parasuis. 45 
 46 
 47 
 48 
Introduction 49 
Haemophilus parasuis is a Gram-negative bacterium commonly found in the upper respiratory tract of the 50 
pig and, in 1910, it was identified as the causative agent of a globally prevalent systemic disease of pigs 51 
known as Glässer’s disease. The more severe presentations of this disease include arthritis, meningitis, 52 
polyserositis and septicaemia, as well as pneumonia (1–5). Based on statistics from the USA, H. parasuis is 53 
the leading cause of mortality (alongside the PRRS virus) in nursery herds, and is the third most important 54 
bacterial pathogen affecting finisher herds (6). H. parasuis also contributes to multi-factorial porcine 55 
respiratory disease complex, the leading cause of mortality in grower-finisher pigs in the USA (7). 56 
Diagnostic submissions to veterinary investigation centres of the Animal and Plant Health Agency (APHA) 57 
in 2013-14 recorded the highest annual rate of diagnosis of disease incidents due to H. parasuis in England 58 
and Wales since 2002 (8, 9). In the third quarter of 2013, the diagnostic rate reached nearly 8% of 59 
diagnosable submissions (8, 9)This disease characteristically manifests post-weaning and is associated with 60 
the loss of maternally-derived antibodies and the endemic presence of the bacterium in herds (1, 5). 61 
The treatment and prevention of Glässer’s disease is implemented via strategic delivery in feed or water of 62 
penicillin-based antimicrobials. On-going treatment may be administered to successive batches of 63 
susceptible pigs for several months after an outbreak to ensure the herd’s full recovery (5, 10, 11). Regular 64 
medication of farmed livestock is of concern as antimicrobial resistance may be selected by the prolonged 65 
use of these drugs. Antimicrobial resistance in H. parasuis has been reported in China and Spain, where the 66 
majority of H. parasuis strains are resistant to enrofloxacin and trimethoprim (10, 12, 13). Control of stock 67 
movement into and out of the herd is currently the best method of prevention, as it reduces the risk of 68 
introducing new strains (5, 14, 15).  69 
Current commercially available vaccines are bacterins which are protective only against strains of the same 70 
serovar (16–18), and which primarily target the disease-causing serovars 4 and 5 with limited cross-71 
protection against others (5, 19, 20). It is possible to make autogenous vaccines in response to an outbreak of 72 
Glässer’s disease, which can be useful if the serovar is different to the commercial vaccines (21), but this is 73 
an expensive and time-consuming option. In addition, multiple isolates, often of different serovars, may be 74 
present within an individual or a herd, which can result in the wrong isolate being chosen for the production 75 
of the autogenous vaccine.  76 
Serotyping is the most frequently used sub-typing method for H. parasuis, as it is important for guiding the 77 
vaccination strategy to try to prevent future outbreaks. The current serotyping scheme, based on reactions 78 
between antisera and surface antigens, classifies the bacteria into fifteen serovars, with a considerable 79 
number of non-typeable (NT) isolates observed (22, 23). Most commonly isolated from the field are 80 
serovars 4, 5, and 13 (24–27). However, isolates are collected predominantly from severely affected 81 
individuals or clinical cases from within a herd, with only a single colony studied from those cultured from a 82 
swab. As multiple infections of the same individual and within herds can occur (25, 27–29), there may be 83 
additional isolates that are contributing to disease in animals that are not commonly investigated. The site of 84 
isolation is also very important, as isolates cultured from the joints or from meninges have survived serum 85 
killing and phagocytosis and so are highly likely to be virulent whereas if samples are taken from the upper 86 
respiratory tract or the lung there is a higher chance of the isolate being a co-infection rather than the isolate 87 
responsible for the disease.  This might well introduce sampling bias and the relative proportions of different 88 
serovars amongst isolates actively causing disease and carriage isolates in pig populations may vary from 89 
the commonly reported serovars 4, 5 and 13 (24–27).  90 
The Kielstein-Rapp-Gabrielson serotyping scheme was the first to identify the fifteen serovars of H. 91 
parasuis in 1992 using the gel immune-diffusion assay (GID) (23), which has since been superseded by an 92 
indirect haemagglutination assay (IHA) (30–32); this has increased the proportion of typeable strains from 93 
60% to 80%. An isolate may be reported as non-typeable if there is no observable reaction, or when four or 94 
more different antisera react with the same isolate. A serotyping result can include cross-reactions when two 95 
or three antisera react with an isolate, and this is common for field isolates using both serotyping methods 96 
(23, 25, 30, 33). In these circumstances the “strongest” reaction is chosen as the main serotyping result, but 97 
this can be dependent on a visual interpretation by the worker, so human error is introduced into the test. 98 
Therefore, even with 80% of isolates being “typeable”, this success rate is susceptible to errors that reduce 99 
accuracy. Improvements in accuracy of the serotyping of H. parasuis would aid the understanding of the 100 
epidemiology of this pathogen and allow optimization of vaccination strategies for prevention of disease.  101 
There are other drawbacks of the IHA serotyping assay including the difficulty of consistently producing 102 
specific antisera against several reference strains (30), variation in growth conditions or growth rates 103 
between isolates, the very small number of laboratories that currently perform this test, and repeatability or 104 
robustness of methods and results between these laboratories (23, 31, 34, 35). The method is also time-105 
consuming, expensive and requires pure culture of an isolate.   106 
Molecular typing should be considered as a potentially more accurate and consistent test.  These techniques 107 
have been developed for other bacteria based on the genes involved in biosynthesis of extracellular 108 
polysaccharide structures such as LPS or capsules (36–39). These are also likely to be the dominant 109 
components of the serotyping antigens for H. parasuis based on the antigen preparation techniques for both 110 
the GID and IHA methods (22, 23, 30, 31). Genes encoding these surface components were therefore the 111 
elements of the genome investigated for molecular serotyping markers. Analysis of the first complete H. 112 
parasuis genome sequence (strain SH0165) identified a 14kb polysaccharide biosynthesis region that was 113 
proposed to encode O-antigen, with twelve coding sequences in the same transcriptional direction. It was 114 
later proposed that this is in fact a group 1 capsule locus based on the presence of the homologues of the wza, 115 
wzb and wzc genes, and that it is responsible for considerable serovar-specific variation (40–43). 116 
Furthermore, there is a strong association between the presence of particular capsule loci and serotyping 117 
results (44), with 85% of reference strains studied having the same serotyping result from in silico analysis 118 
and IHA. Those isolates with different results matched to one of the cross-reactions in the IHA result. In 119 
addition, isolates that had been non-typeable (NT) by IHA contained a capsule locus that matched one of the 120 
fifteen reference strains, with two exceptions (43, 44). These two isolates had capsule genes similar to those 121 
identified in serovars 6 and 8, but they had not been assembled onto a single contiguous sequence (contig) or 122 
capsule locus and so they require further investigation.  123 
Here we describe the design of a molecular serotyping PCR, based on variation within the capsule loci, 124 
capable of discriminating between fourteen of the fifteen serovars of H. parasuis. In addition, a new species-125 
specific molecular marker for H. parasuis was identified and included in the multiplex PCR (mPCR). 126 
127 
Materials and Methods 128 
Isolate collections 129 
For the design of this molecular serotyping test, we used a previously described (44) collection of 212 130 
isolates of H. parasuis, 117 of which had been serotyped by IHA. This collection included isolates cultured 131 
from pig tissues during diagnostic investigations at the APHA from farms in England and Wales between 132 
1993 and 2011, isolates from Denmark, Spain and Australia, as well as the fifteen serotyping reference 133 
strains. This collection included disease- and non-disease-associated isolates, all of which were genome 134 
sequenced by genomic DNA (gDNA) extraction and paired-end Illumina sequencing as described previously 135 
(44). The genome sequences of these isolates were examined for the presence of a capsule locus and for all 136 
but two of them a serovar could be predicted in silico based on the capsule genes (44). A subset of 150 137 
isolates from of this original collection was used for the validation of the mPCR, 117 of which had been 138 
serotyped by IHA and all of which a serovar had been predicted by in silico analysis. This subset included 139 
isolates representing all fifteen serovars and included those previously serotyped including those with cross-140 
reactions (n=22), all non-typeable isolates (n=19) and a selection of isolates that have not been serotyped 141 
(n=33).  142 
An additional 84 disease-associated isolates of H. parasuis were collected by the APHA during 2013 and 143 
2014; we have called this the additional isolate collection. Sixty-six of these were serotyped by Innovative 144 
Veterinary Diagnostics (IVD), Germany, using IHA and were of a variety of serovars (serovar 1, 2, 4, 5, 6, 9, 145 
13, 14, 15) as well as non-typeable isolates (n=15). Nine of the isolates had cross-reactions reported in their 146 
serotyping results. The remaining eighteen isolates had not been tested by IHA and so were of unknown 147 
serovar. This additional isolate collection, with unknown capsule loci, did not contribute to the original 148 
design of serovar-specific markers and therefore it enabled objective evaluation of the new mPCR.  149 
Isolates of closely-related Pasteurellaceae including Actinobacillus indolicus, Actinobacillus minor, 150 
Actinobacillus porcinus and Actinobacillus porcitonsillarum were identified from routine diagnostic 151 
investigations at the APHA and were also genome sequenced (European Nucleotide Archive: ERS132116, 152 
ERS132148, ERS132149, ERS132152-ERS132156, ERS132158-ERS132160, ERS132162-ERS132165, 153 
ERS132169, ERS132170).  These genomes were evaluated using BLASTn against the primers designed for 154 
H. parasuis, as they are from species that are most likely to cross-react. These isolates together with further 155 
field isolates of Actinobacillus pleuropneumoniae (n=3), Bordetella bronchiseptica (n=1) and Streptococcus 156 
suis (n=3), all common bacteria in the upper respiratory tracts of pigs, were used in this study as part of a 157 
negative control panel for the mPCR.  158 
Species-specific marker design 159 
A Perl script was used to produce a draft core genome of H. parasuis using the genome sequences of the 160 
original collection (n=212) (44). The protein-coding sequences from the published complete genome of H. 161 
parasuis SH0165 (45) were compared using tBLASTn to the H. parasuis genomes. If a coding sequence had 162 
80% identity over 80% of the length of the gene to a contig in all of the H. parasuis genomes, then the gene 163 
was considered to be part of the “core” genome. This list represents the most conserved genes in the H. 164 
parasuis genome. The SH0165 Fasta sequence for each gene from the core genome was compared to the 165 
non-redundant (nr) NCBI database using BLASTn to identify genes with matches only to H. parasuis. These 166 
core genes were also compared by BLASTn with the genome sequences of the other Pasteurellaceae 167 
isolates.  Genes with matches in H. parasuis only were taken forward as potential species-specific markers. 168 
The alignments of the genes were assessed using alistat (46) to study the average alignment identity and 169 
minimum alignment identity between two sequences in the alignment. Genes with greater than 95% average 170 
alignment identity were chosen to create a shortlist of potential species-specific markers with a variety of 171 
amplicon sizes.  172 
Serotyping mPCR Design 173 
The capsule loci of the fifteen serovar reference strains were previously sequenced and annotated (43). The 174 
majority of isolates of the same serovar shared high levels of identity in their capsule loci, as expected (>95% 175 
for the majority of serovars) (44). Where loci did not match within the same serovar, the majority of the 176 
capsule loci matched to a recorded cross-reaction (44). Twenty-two isolates in the original isolate collection 177 
had recorded cross-reactions, and four of these isolates matching to the minor reaction rather than the 178 
dominant serovar in the cross-reaction results. A further ten isolates in the original isolate collection had 179 
different results to the IHA serotyping result. The agreement between the IHA serotyping and the capsule 180 
loci was tested using an un-weighted Cohen’s Kappa test, excluding the NT isolates (47)  Differences in the 181 
gene composition were found between the capsule loci of the reference strains i.e. between different 182 
serovars, with the exception of serovars 5 and 12 which have 97% identity across the capsule locus (37) and 183 
a shortlist of genes found in only one or two of the fourteen known capsule loci was made, from which to 184 
design primers for distinguishing the serotypes. The original capsule variation diagram from Howell et al. 185 
2013 has been adapted to show the gene differences and target genes for the multiplex design (Figure S1).   186 
Primer design 187 
Primer design for the species-specific marker and serotyping markers was as follows. Primer3 188 
(http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi/) was used to design primers between 21 189 
and 30 bases in length with 40-60% G+C content based on recommendations for multiplex PCR (mPCR) 190 
design. The primers for each gene were compared, using BLASTn with a word size of 7, to the nr database 191 
and the closely-related Pasteurellaceae bacterial genomes to check for any non-specific primer matches that 192 
would rule out any primer sequences. The primers were also compared to the H. parasuis genomes using 193 
BLASTn to look for those that matched all of the expected isolates, with only one match and 100% identity. 194 
All those that passed these checks were then aligned against the target gene and product sizes were 195 
estimated based on all combinations of primers. For several genes the primers had to be re-designed 196 
manually when no suitable primer met the requirement for the range of product sizes. Primer-dimer and 197 
hairpin structures were predicted for all of the primer combinations using National Institute of Standards and 198 
Technology Primer Tools (http://yellow.nist.gov:8444/dnaAnalysis/primerToolsPage.do) and any 199 
problematic primers were removed from the shortlist. A pair of primers was chosen for each gene, which 200 
would give approximately 20-50 bp separation between all amplicons when combined into an mPCR. 201 
Primers were obtained in dehydrated, de-salted form from Sigma-Aldrich (Haverhill, Cambridge). The final 202 
target genes and primers for the mPCR are shown in Table 1. 203 
Primer optimisation 204 
All primers were initially tested using gradient PCRs using OneTaq® Quick-Load® 2X master mix with 205 
standard buffer (New England BioLabs) following the product specifications and protocols. Amplification 206 
of the targets was initiated at 94ºC for 30 seconds, followed by 30 cycles of 3-step cycling comprising 207 
denaturation at 94ºC for 30 seconds, annealing at a temperature range for the gradient PCR between 52-64ºC 208 
for 30 seconds, 68ºC for 60 seconds for extension and a final extension of 68ºC for 5 minutes. Each PCR 209 
reaction contained 12.5µl OneTaq® Quick-Load® 2X master mix, 0.25µl of each primer (at 20µM each), 210 
2µl of gDNA for each isolate (at >10ng/µl) and 10µl UltraPure H2O (Life Technologies) to a final volume 211 
of 25µl. For the individual serovar-specific primers, the reference strain of each serovar was used as a 212 
positive control and an isolate from a different serovar was selected as a negative control. UltraPure H2O 213 
was used as a negative control for all PCRs. Gel electrophoresis was performed in 2.0% agarose in 1x TBE 214 
with 5% Sybrsafe dye (Invitrogen), at 120V for 50 minutes using the Quick-Load® 100 bp DNA Ladder 215 
(New England BioLabs) as the molecular size standard. All results were analysed using a GelDocTM XR 216 
Imager (Bio-Rad). Each pair of primers was then tested on the panel of reference strains for the fifteen 217 
serovars (Table S1) using 25µl PCR reactions and the PCR protocol above with the consensus annealing 218 
temperature of 64ºC from the individual gradient PCRs. PCR purification was performed using a 50µl PCR 219 
reaction and the QIAquick PCR Purification Kit (Qiagen) as per the manufacturer’s instructions.  PCR 220 
products were sequenced using the Source Biosciences Sanger sequencing service. Sequences of the 221 
products were aligned with the target gene and primers using SeaView (48). 222 
One-step mPCR 223 
The successful primers for the mPCR were combined to create a 50µM primer mix using 1xTE buffer. 224 
DMSO (Sigma-Aldrich) was added to the PCR reactions at 1% of the total reaction volume and the 225 
annealing temperature was reduced to 58ºC to improve the production of bands of equal intensity. The 226 
primer mixes were also optimised aiming for equal intensity for each amplicon, with a ratio of 1:0.25 227 
serovar-specific primers to species-specific primers. The final PCR reaction mix included 12.5µl 228 
OneTaq® Quick-Load® 2x master mix, 3µl of the primer mix, 2µl of gDNA for each isolate (at >10ng/µl) 229 
and 7.25µl UltraPure H2O to a final volume of 25µl. Gel electrophoresis for the mPCR was extended to 90 230 
minutes for better separation of the amplicons.  231 
The mPCR was tested on 234 isolates (a subset of 150 from the original isolate collection and the additional 232 
isolate collection of 84 isolates) and was repeated in triplicate using separate master mixes to demonstrate 233 
the repeatability and accuracy of the mPCR. For the subset of the original isolate collection the mPCR 234 
results were compared to the in silico serovar predictions. For the additional isolate collection it was only 235 
possible to compare the mPCR result to the IHA serotyping result if known.  236 
Genomic DNA extraction requires pure culture, can be time consuming, and adds additional cost to the 237 
diagnosis procedure and so colony PCR methods can be more convenient for diagnostic laboratories. 238 
Therefore, for comparison, 20 isolates from the additional isolate collection were also tested using a colony 239 
PCR method. A loopful of bacteria from a passaged plate of pure culture was resuspended in 50µl of 240 
UltraPure H2O, which was heated to 100ºC for 30 minutes, and centrifuged at 4,000 g for 1 minute before 241 
the supernatant was used in the mPCR reaction. The same volume of supernatant was used in the mPCR 242 
reaction as the volume that was used for pure genomic DNA. The results of mPCR were compared to those 243 
of the IHA serotyping method (where available).  244 
Limit of detection of the mPCR 245 
The concentration of gDNA was measured for five reference strains (strain name – serovar: HS145 – S1, 246 
SW140 – S2, Nagasaki – S5, C5 - S8, D74-Aus – S9, IA84/17975 - S13) using a Qubit fluorometer (Life 247 
Technologies) with broad-range standards. Six serial dilutions of this DNA in UltraPure H2O were used as 248 
template in the mPCR to estimate its limit of detection. This was then calculated as genome/µl based on the 249 
average genome size of 2.26Mb. 250 
251 
Results 252 
Design of the serotyping mPCR 253 
Based on the in silico analyses of the capsule loci (44), a serovar was predicted for all except two of the H. 254 
parasuis isolates in the original collection (n=212), including those that had previously been determined as 255 
NT using the IHA method (44). Cohen’s Kappa (47) was used to test agreement between the IHA and in 256 
silico analyses (for isolates where both results were available) and was statistically significant (p<0.01) with 257 
the individual serovars treated as categories. The two exceptions had incomplete capsule locus sequences, 258 
but the genes identified were highly similar to those from capsule loci from serovars 6 and 8.  259 
Fourteen isolates were discrepant between the in silico serovar prediction and the IHA results with four 260 
isolates matching to the cross-reaction: a serovar 12 (2,4) result was identified as a serovar 2 isolate, and 261 
serovar 7 isolates with cross-reactions identified as serovar 4. The remaining isolates were a serovar 2 262 
identified as a serovar 1, a serovar 7 identified as a serovar 9, a serovar 7(2) identified as a serovar 4, three 263 
serovar 7 identified as serovar 4, a serovar 11 identified as a serovar 13, a serovar 13 identified as a serovar 264 
5 or 12 and two serovar 14 isolates identified as a serovar 13.  265 
Given the success of predicting serotype by in silico analysis the serovar prevalence of the 117 isolates 266 
which had been serotyped by IHA in comparison with the in silico prediction of serotype of those isolates in 267 
the original collection was reassessed (Figure 1, (44)). From the original IHA serotyping results, serovars 5, 268 
NT, 4, 7 and 13 were the most prevalent serovars, in order of frequency. In comparison, the in silico results 269 
of all isolates showed unequivocally that serovar 4 was the most prevalent, followed by 5, 13 and 7 and none 270 
of the isolates was NT by in silico analysis, in comparison to 19 out of 117 by IHA serotyping.  271 
The large amount of genetic variation between the capsule loci of the fifteen serovars was chosen as the 272 
target for a molecular serotyping assay. The assay was designed using a wide variety of genes from within 273 
the capsule loci including an aminotransferase, glycosyltransferases, O-antigen flippase and genes with 274 
unknown function; overall these genes share less than 51% identity at the nucleotide level. The target genes 275 
amongst the variable region can be seen in Figure S1.  It was not possible to detect differences between 276 
serovars 5 and 12 based on the DNA sequences of the capsule loci from any of the examples in the original 277 
isolate collection. Even upon detailed analysis of the whole genomes of serovar 5 and 12 isolates it was not 278 
possible to identify sequence markers to distinguish between these serovars, indicating that there must be a 279 
subtle difference in expression of a gene or genes, or that the difference between serovars 5 and 12 is an 280 
artefact of the IHA typing antibodies.  This finding is consistent with the high frequency of cross-reactions 281 
between these serovars according to the IHA test (30). At least one target gene per serovar was identified 282 
(counting serovars 5 and 12 as the same serovar) except for serovar 1, where the same gene was also 283 
identified in serovars 2 and 11. A gene of unknown function (funB) was chosen as the marker for serovar 1, 284 
which was also identified in serovar 11 and was highly similar to another gene of unknown function in 285 
serovar 2 (funE). The distinguishing primers for serovar 2 were designed against a divergent wzx gene and 286 
the amtA gene was used to identify serovar 11 (Figure 2). By testing the serovar-specific primer pairs 287 
individually it was shown that each pair gave an amplicon of the expected size, each of which was only 288 
produced by the expected serovar (Figure 2), and each of which had the correct DNA sequence. The banding 289 
patterns produced by the reference strains in the serovar-specific PCRs and the new H. parasuis species-290 
specific (sp-sp) marker, with an amplicon size of 275 bp, is shown in Figure 2. This sp-sp marker 291 
(HPS_219690793 - unknown function) was chosen from a shortlist of highly conserved genes from the core 292 
genome, as it fitted best with the serovar-specific amplicon sizes.  293 
During the optimisation of the mPCR, PCR product purification was performed for each pair of primers 294 
using two or three isolates of each serovar and alignments of the sequenced PCR products with the target 295 
gene showed that they were the correct products. The specificity of the serotyping mPCR primers was tested 296 
against six other species commonly found in the upper respiratory tract of the pig including closely related 297 
Pasteurellaceae and other pig pathogens. No products were amplified from these other species strongly 298 
indicating that these primers are specific for H. parasuis (Figure 3). Using DNA isolated from six reference 299 
strains of H. parasuis the average minimum concentration of DNA detectable by the mPCR was determined 300 
to be 1 ng/µl for an individual pure gDNA preparation, or 4.29x105 genomes/µl across the serovars (Figure 301 
4). 302 
Validation of the serotyping multiplex 303 
The molecular serotyping assay was validated using 150 isolates, covering all fifteen serovars, including 117 304 
isolates that had been previously serotyped by IHA, including 19 isolates that were deemed non-typeable. A 305 
summary of the results of this validation exercise and a comparison with the original IHA results and in 306 
silico serovars are shown in Table 2, The mPCR produced the predicted amplicons at the expected sizes 307 
based on the predicted serovar from the in silico analyses (44) and so was 100% accurate. A serovar could 308 
be assigned to every isolate by the mPCR and no cross-reactions were observed. The two isolates with 309 
incomplete capsule loci were typed as serovars 6 and 8 by the mPCR. For 33 isolates the serovar identified 310 
by IHA was different from that assigned by the in silico or mPCR methods. These included the 19 isolates 311 
that were NT by IHA, which were identified as serovars 4, 5, 6, 7, 8, 9, 13 and 14 by the mPCR (Table 2) 312 
and the remaining isolates matched to the minor cross-reactions or the previously mentioned discrepancies 313 
between the capsule types and the IHA results. 314 
A summary of the results of the mPCR for the additional collection of 84 isolates, collected during 2013-315 
2014, is shown in Table 3. Of the 66 isolates previously tested by IHA, in only 51 could a serotype be 316 
determined and 15 were classed as NT all of which could be assigned a serovar by the mPCR.  There were 317 
also six isolates in this collection that were assigned different serovars when tested by mPCR versus IHA.   318 
Overall, the IHA serotyping and the in silico serovar predictions were 90% concordant. From these results it 319 
is clear that serovar 4 was the most prevalent disease-causing serovar in the UK in the period 2013 - 2014, 320 
with serovar 5 next most prevalent. All results from the colony PCR were identical to the results using 321 
gDNA (data not shown).  322 
Discussion 323 
We have developed a multiplex PCR for rapid molecular serotyping of H. parasuis based on genetic 324 
variation within its capsule locus. This mPCR discriminated between all serovars of H. parasuis except 325 
serovars 5 and 12, in which the capsule loci are identical (43).  The high similarity in gene content of the 326 
capsule loci of serovars 1, 2 and 11, which is likely to be due to diversification from a single precursor 327 
capsule locus (43), made the identification of a single specific marker for these serovars more difficult but 328 
we have shown that they can be reliably distinguished using the primer pairs described here. 329 
So far, despite our extensive efforts, no gene to differentiate between serovars 5 and 12 has been identified 330 
from the available whole genome sequences of these serovars. In future it may be possible to identify a 331 
definitive genetic determinant that is responsible for the separation of these two serovars, but it is also 332 
possible that these are in fact not separate serovars. To determine if serovars 5 and 12 really are distinct it 333 
may be necessary to study their capsule structures or the composition of the antigens used in the IHA 334 
serotyping assay more closely. This might point, for example, to a difference in gene expression, rather than 335 
the presence or absence of an allele, as the determinant of the difference between 5 and 12 picked up by 336 
typing anti-sera. In the UK the Porcilis Glässer vaccine cross-protects  (18) between serovar 5 and 12 and so 337 
no immediate negative consequences can be seen from the grouping of serovar 5 and 12 in this mPCR assay. 338 
Conventionally, IHA serotyping would be considered the gold standard with which to compare our mPCR 339 
results. However, IHA serotyping has several well-known drawbacks (non-typeable isolates, cross-reactions, 340 
difficulties in producing anti-sera) that make it somewhat unreliable and difficult to perform. We previously 341 
identified a high level of association between the capsule loci or “capsule type” of an isolate and the IHA 342 
serotyping results (44). Based on these results we have proposed that the capsule locus is likely to encode 343 
the dominant component of the serotyping antigens (43, 44). All non-typeable isolates tested with the mPCR 344 
were assigned to a capsule type, with only 12% of isolates assigned to a different serovar than predicted by 345 
IHA excluding NT isolates. The majority of isolates with cross-reactions matched to the strongest cross-346 
reaction, but four isolates matched to the minor cross-reaction in the serotyping result. The accuracy of the 347 
mPCR can be considered in two ways. First, if we compare the mPCR results to the IHA results, taking the 348 
latter as the “gold standard”, then the mPCR was 87% accurate for isolates of known serovar for the original 349 
collection and 78% accurate for the additional isolate collection. However, the mPCR was able to type 100% 350 
of isolates tested compared to IHA identifying only 83% of the original collection and 77% of the additional 351 
collection. Therefore it is perhaps more appropriate to consider that the in silico serovar is the new gold 352 
standard, in which case we estimate that the IHA serotyping method is only 72% accurate based on the 353 
concordance between the two methods and the total number of isolates tested. This takes into account the 354 
NT isolates, and those with results that differ between the two methods.  It is of course possible that IHA is 355 
truly reflecting the effective serovar of the bacterium when it is being tested in the laboratory, in that capsule 356 
gene expression might be off under these conditions, but we contend that the mPCR is more useful in these 357 
circumstances if the serotyping is being performed to obtain maximum information about the isolate, and to 358 
help to define disease potential. 359 
Surveillance of this bacterium is focused on the isolates that are responsible for clinical disease cases, and 360 
only a single purified colony isolated from a case is usually serotyped due to the expense of the current IHA 361 
test. This means that potential multiple infections (4, 29, 49) are not routinely monitored in pig herds 362 
(whether disease-associated or carriage); therefore the real prevalence of serovars may differ from that 363 
reported in the literature. In contrast, this mPCR can use a “loopful” of bacteria, whether from passaging of 364 
a colony or using multiple colonies grown from a clinical sample that could contain colonies of different 365 
serovars, and thus we might be able to detect multiple serovars of H. parasuis at once from a single clinical 366 
sample. This mPCR would also allow the testing of multiple purified single colonies of H. parasuis that may 367 
be grown from a single clinical sample. These surveillance strategies would give more comprehensive 368 
figures for carriage rates and co-infection rates for the different serovars within individuals or at the herd 369 
level. The availability of molecular methods for detection of this fastidious organism in post-mortem tissues 370 
would allow for more widespread application of the test, and might enable a more accurate understanding of 371 
the true contribution of different serotypes to clinical disease. For example, serotype-based differences in 372 
ease of culture and isolation may exist that can be overcome by new molecular detection methods. In the 373 
future, it may be also possible to detect H. parasuis in more accessible sample sites such as the nasal cavity 374 
or oral fluid. This would pave the way for prospective sampling of herds. The removal or reduction in cross-375 
reactions will also make a clearer picture for the decision to vaccinate; particularly between serovars 4 and 7, 376 
which is a common cross-reaction in the UK. Rapid serovar identification will enable earlier introduction of 377 
prophylactic vaccination. However, the presence of multiple isolates of H. parasuis in the same animal (4, 378 
29, 49) may mean that care needs to be taken when interpreting the results. There have been reports that 379 
some serovars are more virulent than others for example serovars 5 and 13 (1, 23, 50) and mPCR results will 380 
help to determine whether or not multiple “virulent” serovars or a mixture of “virulent” and “avirulent” 381 
serovars is present in a sample.   382 
In summary, we have developed a molecular serotyping mPCR that can differentiate fourteen of the fifteen 383 
serovars of H. parasuis. A total of 234 H. parasuis isolates from two isolate collections were tested using 384 
this new assay and 100% of isolates were serotypeable using the mPCR.   There were no ambiguous cross-385 
reactions between different serovars of H. parasuis, nor were there any cross-reactions with any other 386 
commensal or pathogenic bacteria tested to date. Of the isolates tested by mPCR, 12% had results that 387 
differed from the IHA serotyping assays (NT isolates excluded), and much of this variance is explained by 388 
previously discussed difficulties with the IHA method. Therefore this molecular serotyping assay is a 389 
significant improvement on the current methods, reducing non-typeability, ambiguity and cost of testing. 390 
The mPCR method described is fast, simple and transferable to a molecular diagnostic laboratory with basic 391 
equipment and can be performed on crude gDNA derived directly from bacterial colonies.  392 
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Figure Legends: 417 
Figure 1: Serovar prevalence of 117 isolates that had been serotyped by IHA (blue) in comparison with the 418 
in silico serovar predicted for the same isolates based on analysis of the capsule loci (red). Agreement 419 
between the IHA and in silico serovar prediction was tested using unweighted Cohen’s kappa test, with p-420 
value 0.0000128, excluding the NT isolates.  421 
Figure 2: Band patterns for the molecular serotyping PCR for all 15 serovars of H. parasuis. M – Quick-422 
Load 100 bp DNA Ladder (NEB), and S1-S15 represent the fifteen serovars of H. parasuis. Sp-sp denotes 423 
the species-specific marker. 424 
Figure 3: Negative control panel showing specificity of the primer sets across a range commensal and 425 
pathogenic bacteria found in the pig respiratory tract (Haemophilus parasuis positive controls serovar 2 426 
and serovar 5, Actinobacillus minor, A. porcinus, A. indolicus, Streptococcus suis, A. pleuropneumoniae, 427 
Bordetella bronchiseptica). M - Quick-load 100 bp marker (NEB) and H2O as the negative control. 428 
Figure 4: Determination of the limit of detection for the serotyping multiplex based on pure genomic DNA 429 
for the reference strains of serovars 1, 2, 5, 8, 9, and 13. The unit of genome/µl is used. M - Quick-load 100 430 
bp marker (NEB) and H2O as the negative control. 431 
 432 
 433 
 434 
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Tables 440 
Table 1: Serotyping multiplex primers and estimated product sizes 441 
Gene Forward Primer 5’ to 3’ Reverse Primer 5’ to 3’ Serovar 
target 
Product 
Size (bp) 
funB CTGTGTATAATCTATCCCCGATCATCAGC GTCCAACAGAATTTGGACCAATTCCTG 1 180 
wzx CTAACAAGTTAGGTATGGAGGGTTTTGG
TG 
GGCACTGAATAAGGGATAATTGTACTG 2 295 
glyC CATGGTGTTTATCCTGACTTGGCTGT TCCACATGAGGCCGCTTCTAATATACT 3 650 
wciP GGTTAAGAGGTAGAGCTAAGAATAGAG
G 
CTTTCCACAACAGCTCTAGAAACC 4 320 
wcwK CCACTGGATAGAGAGTGGCAGG CCATACATCTGAATTCCTAAGC 5 or 12 450 
gltI GATTCTGATGATTTTTGGCTGACGGAAC
G 
CCTATTCTGTCTATAAGCATAGACAGG
AC 
6 360 
funQ CTCCGATTTCATCTTTTCTATGTGG CGATAAACCATAACAATTCCTGGCAC 7 490 
scdA GGAAGGGGATTACTACTACCTGAAAG CTCCATAGAACCTGCTGCTTGAG 8 650 
funV AGCCACATCAATTTTAGCCTCATCA CCTTAAATAGCCTATGTCTGTACC 9 710 
funX GGTGACATTTATGGGCGAGTAAGTC GCACTGTCATCAATAACAATCTTAAGA
CG 
10 790 
amtA CCATCTCTTTAACTAATGGGACTG GGACGCCAAGGAGTATTATCAAATG 11 890 
gltP GCTGGAGGAGTTGAAAGAGTTGTTAC CAATCAAATGAAACAACAGGAAGC 13 840 
funAB GCTGGTTATGACTATTTCTTTCGCG GCTCCCAAGATTAAACCACAAGCAAG 14 730 
funI CAAGTTCGGATTGGGAGCATATATC CCTATATCATTTGTTGGATGTACG 15 550 
HPS_2
196907
93 
ACAACCTGCAAGTACTTATCGGGAT TAGCCTCCTGTCTGATATTCCCACG All 275 
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 450 
 451 
 452 
Table 2: Summary of the mPCR serotyping results from 150 isolates, showing that the majority of isolates 453 
tested had the same result by IHA serotyping as by the mPCR (n=78). All non-typeable (NT) isolates were 454 
assigned a serovar by the mPCR (n=19). An additional subset of 40 isolates was tested with the mPCR that 455 
had not been tested by IHA serotyping (unknown), all of which were assigned a serovar using the mPCR. 456 
Serovar by mPCR Serovar by IHA   1 2 3 4 5 or 12 6 7 8 9 10 11 13 14 15 NT Unknown Total
1 3 1 2 6 
2 6 1 4 11 
3 2 0 2 
4 13 7 4 5 29 
5 or 12 25 1 1 5 32 
6 4 2 4 10 
7 4 7 4 15 
8 2 1 2 5 
9 1 4 1 1 7 
10 2 0 2 
11 2 0 2 
13 1 9 2 2 3 17 
14 6 1 1 8 
15 2 2 4 
NT                               0 0 
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 467 
 468 
Table 3: Summary of the mPCR serotyping results of the additional isolate collection of UK isolates from 469 
2013 – 2014 (n=84). Cross-reactions in the IHA result were ignored for this comparison. All non-typeable 470 
(NT) isolates were assigned a serovar by the mPCR. The unknown isolates had not been serotyped by IHA at 471 
the time of testing with the mPCR but all were assigned a serovar using this mPCR. 472 
Serovar 
by mPCR 
Serovar by IHA 
1 2 3 4 5 or 12 6 7 8 9 10 11 13 14 15 NT Unknown Total 
1 4 4 
2 3 2 5 
3 0 
4 17 2 6 25 
5 or 12 11 4 4 19 
6 1 1 2 
7 1 3 3 7 
8 1 1 
9 1 1 
10 1 1 
11 0 
13 2 2 1 1 1 7 
14 1 4 5 
15 2 5 7 
 473 
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